Ulcerated Nodular Nasal Basal Cell Carcinoma Successfully Treated With Imiquimod 5% CreamTo the Editor: Basal cell carcinomas (BCCs) represent the most common cutaneous malignancy. It most commonly affects the nose,…
Read More
INTRODUCTIONAlthough there has been a significant increase in the occurrence of malignant melanoma (MM) in the last several decades, screening of patients at increased risk by dermatologists in the office…
Read More
The UC Davis Department of Dermatology is located in Sacramento, California. Our department is made up of 23 clinical faculty members, six research faculty members and 11 volunteer faculty members.…
Read More
Our practice is a university-based referral center with most referrals coming from within the university, a local Veterans Affairs medical center and private practice offices locally and as far away…
Read More
INTRODUCTION Ultraviolet (UV) light represents the major factor in skin photoaging and skin cancerogenesis.1,2 UV exposure causes acute inflammatory changes (such as erythema, edema, and subsequently pigmentation or tanning) and…
Read More
INTRODUCTIONPsoriasis is a chronic inflammatory skin condition characterized by exacerbations and remissions afflicting 1-3 percent of the population.1-3 Forty to fifty percent of patients (in one survey as many as…
Read More
INTRODUCTION Erythema nodosum leprosum (ENL) is an inflammatory event that can occur in patients with multibacillary leprosy. In the skin lesions of ENL, immune complexes and split products of activated…
Read More
INTRODUCTION Psoriasis is a chronic, often lifelong inflammatory skin disease that affects as many as 7.5 million Americans and 125 million people worldwide.1 Traditional treatments, such as topical applications, phototherapy,…
Read More
INTRODUCTION Etanercept (Enbrel,® Immunex-Wyeth, Thousand Oaks, CA) is a recombinant, fully human, soluble, dimeric fusion protein consisting of two copies of the extracellular ligand-binding domain of the human 75 kd…
Read More
INTRODUCTION Imiquimod was approved by the U.S. Food and Drug Administration (FDA) in 1997. The 5% formulation is known under the trade names of Aldara and Beselna. A 3.75% formulation…
Read More
A four-day old Hispanic female was transferred to our institution from an outside hospital for management of hemolytic anemia and a rash on her abdomen. She was born at 35…
Read More